You Own Wall Street › Funds › Biotechnology Portfolio
Biotechnology Portfolio (FBIOX) proxy voting record 2026
Three of its ballots from this season. Vote first, then see what it did with the shares your savings paid for.
The question on the ballot
As filed
Fidelity Select Portfolios files this fund's proxy votes with the SEC once a year. This is what it did with the shares your retirement savings paid for.
SourceProxy-voting record filed by Fidelity Select Portfolios on 2026-08-27 · open the filing · vote table (ProxyVotingTable.xml, 15 MB)
TickerFBIOX · as listed in its latest SEC filing of proxy votes
How it voted, by issue
Fund companies sometimes file the same proposal under different subjects. So that funds can be compared, each proposal is counted under the subject most of the filings we read gave it, the same for every fund on this site. On management's own executive pay resolutions, this fund voted in favour 90.4% of the time across 115 votes.
| Issue | Proposals faced | Backed | Share backed |
|---|---|---|---|
| Climate & environment | 1 | 0 | 0% |
| Corporate governance | 4 | 0 | 0% |
| Other social issues | 1 | 0 | 0% |
Ballots it voted
Gilead Sciences, Inc. · 30 April 2026 · put on the ballot by shareholder · Climate & environment
A report on the risks of ESG and DEI executive compensation metrics
AGAINST Biotechnology Portfolio voted with 3,142,752 shares
“To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.”
SourceFidelity Select Portfolios, Form N-PX filed 2026-08-27 · accession 0000320351-26-000385 · series S000007486 · open the filing
Gilead Sciences, Inc. · 30 April 2026 · put on the ballot by shareholder
Should the person who runs Gilead Sciences also chair the board that supervises them?
Shareholders asked the company to require that the chair of the board be an independent director rather than the chief executive, so that the body overseeing management is not led by the person being overseen.
AGAINST Biotechnology Portfolio voted with 3,142,752 shares
“To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.”
SourceFidelity Select Portfolios, Form N-PX filed 2026-08-27 · accession 0000320351-26-000385 · series S000007486 · open the filing
AbbVie Inc. · 8 May 2026 · put on the ballot by shareholder
Should the person who runs AbbVie also chair the board that supervises them?
Shareholders asked the company to require that the chair of the board be an independent director rather than the chief executive, so that the body overseeing management is not led by the person being overseen.
AGAINST Biotechnology Portfolio voted with 2,558,860 shares
“Stockholder Proposal - to Adopt a Policy to Require an Independent Chair”
SourceFidelity Select Portfolios, Form N-PX filed 2026-08-27 · accession 0000320351-26-000385 · series S000007486 · open the filing
Gilead Sciences, Inc. · 30 April 2026 · put on the ballot by shareholder · Social
A report on the impact of extended patent exclusivities on patient access
AGAINST Biotechnology Portfolio voted with 3,142,752 shares
“To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.”
SourceFidelity Select Portfolios, Form N-PX filed 2026-08-27 · accession 0000320351-26-000385 · series S000007486 · open the filing
Other funds Fidelity Select Portfolios votes
The same filer reports these alongside this one, in the same annual filing.
No 401(k) plan we index offers this fund. Its record is here because the fund files it with the SEC, as every fund must: whoever holds it, in an IRA, a brokerage account or a plan we have not indexed, the fund votes those shares as shown on this page.